The Fed cut the policy rate during the last meeting and pre-committed to another two cuts until the end of 2025. This came despite inflation being above the target for yearsAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business r ...

If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to end Q3, consider joining Out Fox The Street .Analyst’s Disclosure:I/we have a beneficial long position in the shares of SFIX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned i ...

If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to end Q3, consider joining Out Fox The Street .Analyst’s Disclosure:I/we have a beneficial long position in the shares of SFIX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned i ...

There are two key reasons for this. First off, income investing - while sub-optimal from a total returns perspective - offers a much greater degree of consistency over longAt PropNotes, we focus on finding high-yield investment opportunities for individual investors.With our background in professional Prop Trading, we make complex concepts easy to understand and offer clear, actionable insights to help you achieve better returns.All of the analysis we produce is designed to help you make smart decisions in ...

PresentationFormat of this session is going to be just some brief slides to get us going, and then we'll go into a fireside chat and Q&A. So with that, Olivier?Thanks, everyone, for joining us. We'll kick off our next session. My name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team based out of New York. I'm excited to host Repligen Corp for our next session. We're joined by Jason Garland, CFO; and Olivier Loeillot, CEO.Olivier LoeillotPresident, CEO & Director Thank you s ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

JR Research is an opportunistic investor. He was recognized by TipRanks as a Top Analyst. He was also recognized by Seeking Alpha as a "Top Analyst To Follow" for Technology, Software, and Internet, as well as for Growth and GARP. He identifies attractive risk/reward opportunities supported by robust price action to potentially generate alpha well above the S&P 500. He has also demonstrated outperformance with his picks. He focuses on identifying growth investing opportunities that present the most attracti ...

Group 1 - The Annual Meeting of Shareholders of Medexus Pharmaceuticals Inc. is being recorded, and participants consent to the recording and use of personal information disclosed during the meeting [1] - Michael Mueller is introduced as the speaker for the meeting, indicating a formal transition to the main agenda [2]

Core Points - The presentation includes forward-looking statements regarding the company's future plans and expected performance [2][3] - The CEO, Nils Ollquist, is leading the discussion and will provide an introductory statement [1][5] Forward-Looking Statements - The forward-looking statements encompass anticipated benefits from proposed licenses, expected synergies, and projections of future financial and operational performance [3] - Terms indicating future expectations include "may," "will," "anticipate," and "project," which highlight the speculative nature of these statements [2] Risks and Uncertainties - There are inherent risks and uncertainties that could lead to actual results differing significantly from the forward-looking statements, particularly regarding the timing and completion of pending transactions [4] - Factors such as governmental regulatory approvals may impact the anticipated benefits and could lead to the abandonment of certain transactions [4]

Group 1 - The event features a discussion with Lilly's CFO Lucas Montarce and Head of IR Mike Czapar, led by Courtney Breen, a U.S. large-cap pharma analyst at Bernstein [1][2] - The format allows for audience interaction through the Pigeonhole app for questions, indicating a focus on engaging with stakeholders [2]